Botanix Pharmaceuticals LimitedASX: BOT

Sofdra safety and benefit-risk profile reaffirmed

· Issued by Botanix Pharmaceuticals Limited via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Botanix Pharmaceuticals Limited has announced the reaffirmation of the safety and benefit-risk profile of Sofdra, as reported in a major American dermatology journal. The peer-reviewed article analyzed adverse events related to Sofdra from a specific period and found them consistent with the known safety profile of the product. The publication highlights that no unexpected adverse events were identified, reinforcing confidence in Sofdra's performance. Botanix's CEO expressed encouragement regarding the transparent reporting of real-world safety data for Sofdra.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

17 November 2026 Sofdra® safety and benefit-risk profile reaffirmed in major American dermatology journal Key Highlights • An article appearing in The Journal of the American Academy of Dermatology (JAAD) reports a favourable risk-benefit profile of Sofdra® • Peer-reviewed brief report...

Botanix Pharmaceuticals Limited on 6ix

Earlier from Botanix Pharmaceuticals

All Botanix Pharmaceuticals news releases